As of Aug 26
| +0.04 / +0.09%|
The 32 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 56.34, with a high estimate of 69.22 and a low estimate of 44.68. The median estimate represents a +20.15% increase from the last price of 46.89.
The current consensus among 32 polled investment analysts is to Hold stock in Novo Nordisk. This rating has held steady since August, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.